Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV2) in relapsed and refractory lymphomas

Invest New Drugs. 1991 May;9(2):185-6. doi: 10.1007/BF00175086.

Abstract

As part of a program to develop less leukemogenic chemotherapy regimens for the treatment of favorable prognosis Hodgkin's disease, a phase I-II trial of mitoxantrone, etoposide, mitoguazone, and vinblastine was used to treat patients with relapsed and refractory malignant lymphoma and Hodgkin's disease. An overall partial response rate of 41% was observed. Although useful responses were seen, the absence of complete remissions is disappointing.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Drug Evaluation
  • Etoposide / administration & dosage
  • Hodgkin Disease / drug therapy*
  • Humans
  • Lymphoma / drug therapy*
  • Middle Aged
  • Mitoguazone / administration & dosage
  • Mitoxantrone / administration & dosage
  • Prognosis
  • Prospective Studies
  • Recurrence
  • Remission Induction / methods
  • Vinblastine / administration & dosage

Substances

  • Vinblastine
  • Etoposide
  • Mitoxantrone
  • Mitoguazone

Supplementary concepts

  • MV2 protocol